We hold the opinion that the contribution of EZH2 to lymphocyte subpopulation differentiation and function suggested that inhibition of EZH2 has the potential to enhance anti-cancer immunity in certain neoplastic diseases, however, the specific mechanisms involved are yet to be investigated and need to be explored further. This evidence concerns the gene EZH2 and cancer.